The delays, first revealed in Regeneron’s Q2 report, were chalked up to manufacturing issues at Novo Nordisk-owned plants.

Regeneron Pharmaceuticals announced FDA extended review timelines to Q4 2025 for two regulatory submissions related to Eylea ...

Before Novo arrived as its owner, issues at the Bloomington facility caused a two-month delay for Eylea HD’s FDA approval ...

Pharmaceuticals announced that the Food and Drug Administration has extended the target action dates to Q4 of 2025 for two Eylea ...

Regeneron's GAAP diluted EPS for Q4 2023 was $10.19, with non-GAAP diluted EPS of $11.86. Regeneron's lead products played a pivotal role is the company's success in Q4.

Reports Q4 revenue $3.79B, consensus $3.75B. “Regeneron’s (REGN) financial and commercial strength allows for continued investment in our industry-leading R&D pipeline, while simultaneously ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged ...

* Q4 earnings per share view $3.03, revenue view $1.30 billion -- Thomson Reuters I/B/E/S * Regeneron Pharmaceuticals Inc - sees single digit percentage growth over 2016 for eylea U.S. net product ...

Regeneron announced Q4 revenue of $2.17 billion, a 13% increase from the $1.9 billion reported in the same quarter of the previous year. Its revenue total also topped the average analysts' revenue ...

Regeneron Pharmaceuticals, Inc. REGN reported strong fourth-quarter 2021 results, with earnings and sales beating estimates on strong growth in Eylea and Dupixent. Contribution from REGEN-COV, its ...

Regeneron co-markets the autoimmune disease drug with Sanofi (SNY -2.32%). Its portion of sales for Dupixent in Q4 soared 56% year over year to nearly $1.2 billion.

Regeneron Pharmaceuticals, Inc. REGN reported better-than-expected results for the fourth quarter of 2019, wherein both earnings and sales beat estimates. Shares are up in pre-market trading on ...